Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study

I-Te Lee, Yen-Feng Chiu, Chii-Min Hwu, Chih-Tsueng He, Fu-Tien Chiang, Yu-Chun Lin, Themistocles Assimes, J David Curb, Wayne H-H Sheu, I-Te Lee, Yen-Feng Chiu, Chii-Min Hwu, Chih-Tsueng He, Fu-Tien Chiang, Yu-Chun Lin, Themistocles Assimes, J David Curb, Wayne H-H Sheu

Abstract

Background: Metabolic abnormalities have a cumulative effect on development of diabetes, but only central obesity has been defined as the essential criterion of metabolic syndrome (MetS) by the International Diabetes Federation. We hypothesized that central obesity contributes to a higher risk of new-onset diabetes than other metabolic abnormalities in the hypertensive families.

Methods: Non-diabetic Chinese were enrolled and MetS components were assessed to establish baseline data in a hypertensive family-based cohort study. Based on medical records and glucose tolerance test (OGTT), the cumulative incidence of diabetes was analyzed in this five-year study by Cox regression models. Contribution of central obesity to development of new-onset diabetes was assessed in subjects with the same number of positive MetS components.

Results: Among the total of 595 subjects who completed the assessment, 125 (21.0%) developed diabetes. Incidence of diabetes increased in direct proportion to the number of positive MetS components (P ≪ 0.001). Although subjects with central obesity had a higher incidence of diabetes than those without (55.7 vs. 30.0 events/1000 person-years, P ≪ 0.001), the difference became non-significant after adjusting of the number of positive MetS components (hazard ratio = 0.72, 95%CI: 0.45-1.13). Furthermore, in all participants with three positive MetS components, there was no difference in the incidence of diabetes between subjects with and without central obesity (hazard ratio = 1.04, 95%CI: 0.50-2.16).

Conclusion: In Chinese hypertensive families, the incidence of diabetes in subjects without central obesity was similar to that in subjects with central obesity when they also had the same number of positive MetS components. We suggest that central obesity is very important, but not the essential component of the metabolic syndrome for predicting of new-onset diabetes. (

Trial registration: NCT00260910, ClinicalTrials.gov).

Figures

Figure 1
Figure 1
Flow diagram of enrollment of study subjects.
Figure 2
Figure 2
Incidence of diabetes among different numbers of positive components in metabolic syndrome.
Figure 3
Figure 3
The numbers of positive components in metabolic syndrome between subjects with central obesity and without central obesity.

References

    1. García-Puig J, Ruilope LM, Luque M, Fernández J, Ortega R, Dal-Ré R. AVANT Study Group Investigators: glucose metabolism in patients with essential hypertension. Am J Med. 2006;119:318–326. doi: 10.1016/j.amjmed.2005.09.010.
    1. Grandi AM, Gaudio G, Fachinetti A, Bianchi L, Nardo B, Zanzi P, Ceriani L, Guasti L, Venco A. Hyperinsulinemia, family history of hypertension, and essential hypertension. Am J Hypertens. 1996;9:732–738. doi: 10.1016/0895-7061(96)00095-7.
    1. Grandi AM, Gaudio G, Fachinetti A, Piantanida E, Zanzi P, Ceriani L, Guasti L, Venco A. Insulin sensitivity in obese normotensive adults: influence of family history of hypertension. Int J Obes Relat Metab Disord. 1998;22:910–914. doi: 10.1038/sj.ijo.0800693.
    1. Grandi AM, Gaudio G, Fachinetti A, Zanzi P, Bianchi L, Ceriani L, Guasti L, Venco A. Influence of family history of hypertension on insulin sensitivity in lean and obese hypertensive subjects. Eur J Clin Invest. 1997;27:774–779. doi: 10.1046/j.1365-2362.1997.1700725.x.
    1. Shirakawa T, Ozono R, Kasagi F, Oshima T, Kamada N, Kambe M. Differential impact of family history on age-associated increase in the prevalence of hypertension and diabetes in male Japanese workers. Hypertens Res. 2006;29:81–87. doi: 10.1291/hypres.29.81.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486.
    1. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419. doi: 10.1161/01.CIR.0000080897.52664.94.
    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–241. doi: 10.1001/jama.2009.2014.
    1. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc. 2006;105:626–635. doi: 10.1016/S0929-6646(09)60161-3.
    1. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295–300. doi: 10.5551/jat.12.295.
    1. Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther. 2010;87:407–416. doi: 10.1038/clpt.2009.311.
    1. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care. 2004;27:2222–2228. doi: 10.2337/diacare.27.9.2222.
    1. Tsai CH. Metabolic syndrome in non-obese Taiwanese: new definition of metabolically obese, normal-weight individual. Chin Med J (Engl) 2009;122:2534–2539.
    1. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887. doi: 10.1038/nature05488.
    1. Lee IT, Lee WJ, Huang CN, H-H Sheu W. The association of low-grade inflammation, urinary albumin, and insulin resistance with metabolic syndrome in nondiabetic Taiwanese. Metabolism. 2007;56:1708–1713. doi: 10.1016/j.metabol.2007.07.015.
    1. Yoon YS, Lee ES, Park C, Lee S, Oh SW. The new definition of metabolic syndrome by the international diabetes federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised national cholesterol education program: the Korea NHANES study. Int J Obes (Lond) 2007;31:528–534. doi: 10.1038/sj.ijo.0803442.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Ranade K, Hsuing AC, Wu KD, Chang MS, Chen YT, Hebert J, Chen YI, Olshen R, Curb D, Dzau V, Botstein D, Cox D, Risch N. Lack of evidence for an association between alpha-adducin and blood pressure regulation in Asian populations. Am J Hypertens. 2000;13:704–709. doi: 10.1016/S0895-7061(00)00238-7.
    1. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27:1182–1186. doi: 10.2337/diacare.27.5.1182.
    1. Mukai N, Doi Y, Ninomiya T, Hata J, Yonemoto K, Iwase M, Iida M, Kiyohara Y. Impact of metabolic syndrome compared with impaired fasting glucose on the development of type 2 diabetes in a general Japanese population: the Hisayama study. Diabetes Care. 2009;32:2288–2293. doi: 10.2337/dc09-0896.
    1. Freemantle N, Holmes J, Hockey A, Kumar S. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract. 2008;62:1391–1396. doi: 10.1111/j.1742-1241.2008.01805.x.
    1. Wassink AM, Van Der Graaf Y, Soedamah-Muthu SS, Spiering W, Visseren FLj. Smart study group: metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. Diab Vasc Dis Res. 2008;5:114–122. doi: 10.3132/dvdr.2008.019.
    1. Gupta AK, Prieto-Merino D, Dahlöf B, Sever PS, Poulter NR. ASCOT investigators: metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabet Med. 2011;28:941–947. doi: 10.1111/j.1464-5491.2011.03330.x.
    1. Yasuda T, Matsuhisa M, Fujiki N, Sakamoto F, Tsuji M, Fujisawa N, Kimura M, Ishibashi R, Kaneto H, Yamasaki Y, Watarai T, Imano E. Is central obesity a good predictor of carotid atherosclerosis in Japanese type 2 diabetes with metabolic syndrome? Endocr J. 2007;54:695–702. doi: 10.1507/endocrj.K06-210.
    1. Lee J, Ma S, Heng D, Tan CE, Chew SK, Hughes K, Tai ES. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care. 2007;30:343–347. doi: 10.2337/dc06-1866.
    1. Zhao D, Grundy SM, Wang W, Liu J, Zeng Z, Wang W, Wu Z. Ten-year cardiovascular disease risk of metabolic syndrome without central obesity in middle-aged Chinese. Am J Cardiol. 2007;100:835–839. doi: 10.1016/j.amjcard.2007.03.103.
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192644.
    1. Chen LK, Peng LN, Lin MH, Lai HY, Hwang SJ, Chiou ST. Predicting new onset diabetes mellitus in older Taiwanese: metabolic syndrome or impaired fasting glucose? J Atheroscler Thromb. 2009;16:627–632. doi: 10.5551/jat.794.
    1. Sung KC, Seo MH, Rhee EJ, Wilson AM. Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol. 2011;10:108. doi: 10.1186/1475-2840-10-108.
    1. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30:2349–2354. doi: 10.2337/dc07-0525.
    1. Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, Cannavan FP, Moreno H. Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol. 2011;10:24. doi: 10.1186/1475-2840-10-24.
    1. Garber AJ. Obesity and type 2 diabetes: which patients are at risk? Diabetes Obes Metab. 2011. in press.
    1. Tenenbaum A, Fisman EZ. "The metabolic syndrome… is dead": these reports are an exaggeration. Cardiovasc Diabetol. 2011;10:11. doi: 10.1186/1475-2840-10-11.
    1. Conus F, Rabasa-Lhoret R, Péronnet F. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab. 2007;32:4–12. doi: 10.1139/h06-092.
    1. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47:699–713. doi: 10.2337/diabetes.47.5.699.
    1. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes. 2001;50:1771–1777. doi: 10.2337/diabetes.50.8.1771.
    1. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes–a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143:339–342. doi: 10.1210/en.143.2.339.
    1. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med. 2009;26:1185–1192. doi: 10.1111/j.1464-5491.2009.02847.x.
    1. Li WC, Hsiao KY, Chen IC, Chang YC, Wang SH, Wu KH. Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults. Cardiovasc Diabetol. 2011;10:36. doi: 10.1186/1475-2840-10-36.
    1. Esteghamati A, Noshad S, Khalilzadeh O, Morteza A, Nazeri A, Meysamie A, Esteghamati A, Nakhjavani M. Contribution of serum leptin to metabolic syndrome in obese and nonobese subjects. Arch Med Res. 2011;42:244–251. doi: 10.1016/j.arcmed.2011.05.005.
    1. Levi J, Gray SL, Speck M, Huynh FK, Babich SL, Gibson WT, Kieffer TJ. Acute disruption of leptin signaling in vivo leads to increased insulin levels and insulin resistance. Endocrinology. 2011;152:3385–3395. doi: 10.1210/en.2011-0185.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere